1. China Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Sinco Pharmaceuticals Holdings Ltd.

Sinco Pharmaceuticals Holdings Ltd.

HHKEX:6833
0.14
HKD
-0.01
(-6.04%)
363.89MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.79
0.91
0.56
0.5
0.56
0.7
1.21
1.17
1.12
1.25
1.39
- -
Basic EPS, GAAP
0.06
0.06
0.01
-0.12
-0.17
0.01
0.07
0.08
0.03
0.02
0.02
- -
Free Cash Flow per Basic Share
0.02
0.03
-0.03
-0.22
0.15
-0.01
0.05
0.16
0.01
0.14
-0.14
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
- -
Book Value per Share
0.09
0.16
0.28
0.17
0.01
0.03
0.1
0.2
0.3
0.31
0.33
0.34
Tangible Book Value per Share
0.09
0.1
0.23
0.15
0.01
0.03
0.1
0.2
0.26
0.26
0.27
0.28
Basic Weighted Avg Shares
1,200
1,200
1,536
1,615
1,689
1,692
1,692
1,737
2,032
2,033
2,033
2,033
Sales/Revenue/Turnover
950
1,096
859
807
953
1,176
2,050
2,024
2,272
2,540
2,821
- -
Operating Margin (%)
11.19
9.74
3.71
-7.28
-10.64
6.22
7.14
9.62
4.46
4.64
4.14
- -
Depreciation Expense
2
10
11
15
10
10
9
7
11
16
24
- -
Net Income, GAAP
69
70
19
-186
-281
24
118
135
69
42
42
- -
Effective Tax Rate (%)
14.59
19.85
28.28
- -
- -
45.18
13.11
19.3
30.04
57.6
57.5
- -
Profit Margin (%)
7.3
6.35
2.25
-23.04
-29.45
2
5.76
6.67
3.06
1.67
1.49
- -
Working Capital
-30
-52
160
4
-203
-30
15
243
227
201
181
195
LT Debt
- -
- -
- -
- -
- -
- -
3
132
9
7
5
2
Total Equity
123
194
457
273
23
46
164
375
604
628
663
684
Return on Invested Capital (%)
- -
33.86
4.98
- -
- -
16.27
49.68
31.46
9.09
5.74
4.92
- -
Return on Capital (%)
- -
30.76
6.01
- -
- -
17.15
52.24
32.77
10.47
5.55
5.01
- -
Return on Common Equity (%)
- -
46.62
5.94
-50.8
-188.8
66.5
111.17
50.01
14.19
6.88
6.51
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
ST Debt
330
346
226
LT Borrowings
- -
- -
- -
LT Finance Leases
4
4
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,033
2,033
2,033
Market Capitalization
463
376
332

Working Capital

CNY

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
Total Current Assets
1,349
1,512
1,388
Cash, Cash Equivalents & STI
282
308
233
Accounts Receivable, Net
688
510
619
Inventories
44
352
274
Total Current Liabilities
1,145
1,332
1,193
Payables & Accruals
- -
- -
- -
ST Debt
330
346
226
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
61.85%
90.76%
5.55%
Free Cash Flow
50.29%
30.53%
-198.89%
Net Income, GAAP
-86.15%
65.52%
-0.72%
Sales/Revenue/Turnover
13.73%
21.62%
11.07%
Total Cash Common Dividend
- -
- -
-60.15%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2,540
2024
- -
- -
2,821
2025
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.02
2025
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Min Jin
Full Time Employees
261
Sector
Distribution services
Industry
Medical distributors
Address
E5-1805, Global Centre Chengdu SI China
IPO Date
Mar 10, 2016
Website
sinco-pharm.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Sinco Pharmaceuticals Holdings Limited (6833.HK) is an investment holding company primarily engaged in providing marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company operates through three main segments: sale of imported pharmaceutical products, including improved human plasma-based biologics such as Octapharma human albumin solutions from Austria, Sweden, Germany, and France for treating blood volume deficiency, hypoalbuminemia, neonatal hyperbilirubinemia, and acute respiratory distress syndrome; antibiotics like Axetine (cefuroxime sodium injection) for bacterial infections including respiratory, urinary tract, soft tissue, gynecological, and surgical prophylaxis; and other specialties such as Medocef for pneumonia and sepsis, Esafosfina for hypophosphatemia and chronic conditions, Taurolite for gallstone diseases, and Tamifil injection for prostate cancer and endometriosis; research, development, manufacturing, and sales of medical aesthetic products, including polycaprolactone fillers like Type S and projects such as Girl Needle, Secret Needle for aesthetic medicine; and biopharmaceutical cold chain and supply chain services, encompassing warehouse facilities, logistics bases, and platform services for biopharmaceuticals. Sinco Pharmaceuticals maintains an extensive marketing network across 31 provinces, municipalities, and autonomous regions in China, with subsidiaries in mainland China, Hong Kong, Macau, and Singapore, targeting hospitals, clinics, and medical institutions. Founded in 2011 and headquartered in Chengdu, Sichuan Province, People's Republic of China, the company operates as a subsidiary of Risun Investment Limited and listed on the Hong Kong Stock Exchange main board in March 2016. Recent developments include ongoing commercialization acceleration of medical aesthetic products like Girl Needle with expanded clinical trials for new applications aiming for completion in 2025, strategic placing of new shares in 2022 to fund medical aesthetic acquisitions and development including the completion of Deyang Demei Medical Aesthetic Clinic acquisition in December 2022, and continued partnerships with global suppliers such as Octapharma while deepening cooperation with major medical institutions to broaden human albumin indications and introduce innovative biologics.